Intervacc AB Logo

Intervacc AB

Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.

IVACC | ST

Overview

Corporate Details

ISIN(s):
SE0009607252 (+1 more)
LEI:
549300OICIVZBBZRNZ64
Country:
Sweden
Address:
Västertorpsvägen 135B, 129 44 Hägersten
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Intervacc AB is a biotechnology company that develops a new generation of vaccines for animal health. The company utilizes a modern technology platform based on recombinant protein fusions, stemming from research at the Karolinska Institutet and the Swedish University of Agricultural Sciences. Its lead product is Strangvac®, a vaccine against equine strangles. Through its subsidiary Nordvacc, Intervacc has an established sales organization with over 30 years of experience in the European animal health market. Another subsidiary, Mybac-Vettech, provides diagnostic laboratory services. The company's vaccines aim to strengthen animal health and wellbeing while contributing to the reduction of antibiotic use and combating antimicrobial resistance.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Intervacc AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Intervacc AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Intervacc AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-26 Lennart Johansson Other Other 813,474 691,452.90 SEK
2025-02-21 Lennart Johansson Other Other 324,156 275,532.60 SEK

Peer Companies

Company Country Ticker View
Galderma Group AG Logo
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland GALD
GC CELL CORPORATION Logo
Biotech firm offering cell/gene therapy CDMO services and developing immune cell cancer therapies.
South Korea 144510
GemVax & KAEL Co.,Ltd. Logo
Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.
South Korea 082270
Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea 229000
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea 109820
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea 011000
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye GENIL
Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark GMAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.